Emerging therapeutics agents and recent advances in drug repurposing for Alzheimer?s disease

被引:12
|
作者
Neha, Suhel Parvez [1 ]
机构
[1] Jamia Hamdard, Sch Chem & Life Sci, Dept Toxicol, New Delhi 110062, India
关键词
Alzheimer?s disease; Neurodegenerative disorder; Molecular targets; Repurposed drugs; Neuroprotection; CLINICAL-PRACTICE GUIDELINE; TYPE-1 RECEPTOR BLOCKER; MESENCHYMAL STEM-CELLS; CENTRAL-NERVOUS-SYSTEM; AMYLOID-BETA; CHOLINESTERASE-INHIBITORS; TAU PHOSPHORYLATION; NICOTINIC RECEPTORS; INSOMNIA DISORDER; AMERICAN-COLLEGE;
D O I
10.1016/j.arr.2022.101815
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Alzheimer's disease (AD) is a multivariate and diversified disease and affects the most sensitive areas of the brain, the cerebral cortex, and the hippocampus. AD is a progressive age-related neurodegenerative disease most often associated with memory deficits and cognition that get more worsen over time. The central theory on the pathophysiological hallmark features of AD is characterized by the accumulation of amyloid beta (A beta) peptides, also associated with tau proteins (tau) dysfunctioning which leads to distorted microtubular structure, affects the cholinergic system, and mitochondrial biogenesis. This review emphasizes how simple it is to find novel treatments for AD and focuses on several recently developed medications through repurposing that can speed up traditional drug development.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease
    Teeba Athar
    K. Al Balushi
    Shah Alam Khan
    [J]. Molecular Biology Reports, 2021, 48 : 5629 - 5645
  • [2] Recent advances on drug development and emerging therapeutic agents for Alzheimer's disease
    Athar, Teeba
    Al Balushi, K.
    Khan, Shah Alam
    [J]. MOLECULAR BIOLOGY REPORTS, 2021, 48 (07) : 5629 - 5645
  • [3] Recent Advances in Drug Repurposing for Parkinson's Disease
    Chen, Xin
    Gumina, Giuseppe
    Virga, Kristopher G.
    [J]. CURRENT MEDICINAL CHEMISTRY, 2019, 26 (28) : 5340 - 5362
  • [4] Challenges and Opportunities for Consideration of Efavirenz Drug Repurposing for Alzheimer's Disease Therapeutics
    Boyarko, Ben
    Podvin, Sonia
    Greenberg, Barry
    Arnold, Steven
    Juanes, Almudena Maroto
    van der Kant, Rik
    Goldstein, Lawrence
    Momper, Jeremiah D.
    Bang, Anne
    Silverman, James
    Feldman, Howard H.
    Hook, Vivian
    [J]. ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2024,
  • [5] Emerging Therapeutics for Alzheimer's Disease
    Chiang, Karen
    Koo, Edward H.
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 54, 2014, 54 : 381 - 405
  • [6] Emerging therapeutics for Alzheimer's disease
    Vardy, Emma R. L. C.
    Hussain, Ishrut
    Hooper, Nigel M.
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2006, 6 (05) : 695 - 704
  • [7] Recent Advances on Polyoxometalates as Metallodrug Agents for Alzheimer's Disease
    Ma, Mengmeng
    Qu, Xiaogang
    [J]. CHEMICAL JOURNAL OF CHINESE UNIVERSITIES-CHINESE, 2020, 41 (05): : 884 - 891
  • [8] Drug Trafficking: Recent Advances in Therapeutics and Disease
    Sprowl, J. A.
    Sparreboom, A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 92 (05) : 531 - 534
  • [9] Recent advances in Alzheimer’s disease pathogenesis and therapeutics from an immune perspective
    Thai-Duong Nguyen
    Loi Nguyen Dang
    Jung-Hee Jang
    Soyeun Park
    [J]. Journal of Pharmaceutical Investigation, 2023, 53 : 667 - 684
  • [10] Recent advances in Alzheimer's disease pathogenesis and therapeutics from an immune perspective
    Nguyen, Thai-Duong
    Dang, Loi Nguyen
    Jang, Jung-Hee
    Park, Soyeun
    [J]. JOURNAL OF PHARMACEUTICAL INVESTIGATION, 2023, 53 (05) : 667 - 684